0001583648-22-000057.txt : 20220706 0001583648-22-000057.hdr.sgml : 20220706 20220706172600 ACCESSION NUMBER: 0001583648-22-000057 CONFORMED SUBMISSION TYPE: 10-K/A PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220706 DATE AS OF CHANGE: 20220706 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PIERIS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001583648 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 300784346 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-37471 FILM NUMBER: 221069791 BUSINESS ADDRESS: STREET 1: 255 STATE STREET STREET 2: 9TH FLOOR CITY: BOSTON STATE: MA ZIP: 02109 BUSINESS PHONE: 857-246-8998 MAIL ADDRESS: STREET 1: 255 STATE STREET STREET 2: 9TH FLOOR CITY: BOSTON STATE: MA ZIP: 02109 FORMER COMPANY: FORMER CONFORMED NAME: Marika Inc. DATE OF NAME CHANGE: 20130805 10-K/A 1 pirs-20211231.htm 10-K/A pirs-20211231
false2021FY000158364800015836482021-01-012021-12-3100015836482021-06-30iso4217:USD00015836482022-02-24xbrli:shares


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K/A
(Amendment No. 1)
(Mark One)
☒
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2021
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     
Commission file number: 001-37471
PIERIS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Nevada 
EIN 30-0784346
(State or other jurisdiction of
incorporation or organization)		 (I.R.S. Employer
Identification No.)
255 State Street, 9th Floor
Boston, MA
United States
 2109
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code
857-246-8998
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each class Trading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per share PIRS
The Nasdaq Stock Market LLC
Securities registered pursuant to Section 12(g) of the Act:
None
(Title of class)
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ☐    No  ý
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.     Yes  ☐    No  ý
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes ý No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes   ý No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer ☐  Accelerated filer 
☐
Non-accelerated filer 
☒
  Smaller reporting company 
☒
Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ý
The aggregate market value of the registrant's common stock held by non-affiliates of the registrant on June 30, 2021, the last business day of the registrant’s most recently completed second fiscal quarter, based on the closing price on that date of $3.83, was $170,606,113.
As of February 24, 2022, the registrant had 74,077,417 shares of common stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE
Certain information required in Part III of this Annual Report on Form 10-K is incorporated from the Registrant’s Proxy Statement for the 2022 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission.
Auditor Name: Ernst & Young LLP        Auditor Location: Boston, Massachusetts        Auditor ID: 00042

EXPLANATORY NOTE REGARDING THIS FORM 10-K/A

The sole purpose of this Amendment No. 1 on Form 10-K/A (the “Amendment”) is to amend the Annual Report on Form 10-K of Pieris Pharmaceuticals, Inc. (the “Company”) as filed with the Securities and Exchange Commission (the “SEC”) on March 2, 2022 (the “Original Filing”) to refile Exhibit 23.1, Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm (the “Auditor Consent”).

The Auditor Consent has been revised to include consent to the incorporation by reference of Ernst & Young LLP’s report dated March 1, 2022, with respect to the consolidated financial statements of the Company included in the Original Filing, of three additional registration statements filed by the Company which were omitted due to a scrivener's error: Form S-3 (File Nos. 333-256218 and 333-258497) and Form S-8 (File No. 333-258502). This Amendment does not otherwise modify, amend, or update in any way the disclosures contained in the Original Filing. Accordingly, this Form 10-K/A should be read in conjunction with the Original Filing and the Company’s other filings made with the SEC after the date of the Original Filing.




PART IV

Item 15.  EXHIBITS, FINANCIAL STATEMENT SCHEDULES
Item 15(a). The following documents were filed as part of the Original Filing:
Item 15(a)(1) and (2) See “Index to Consolidated Financial Statements” on page F-1 to the Original Filing. Other financial statement schedules have not been included because they are not applicable or the information is included in the financial statements or notes thereto.
Item 15(a)(3) Exhibits
 The following is a list of exhibits filed or incorporated by reference as part of the Original Filing and this Amendment and such exhibits are incorporated herein by reference.
Exhibit
Number
Exhibit DescriptionIncorporated by
Reference herein
from Form or
Schedule		Filing DateSEC File /
Registration
Number
Acquisition Agreement, dated as of December 17, 2014, by and among the Registrant, Pieris AG and the former stockholders of Pieris AG named thereinForm 8-K (Exhibit 2.1)December 18, 2014333-190728
Amended and Restated Articles of Incorporation of the RegistrantForm 8-K (Exhibit 3.1)December 18, 2014333-190728
Certificate of Designation of Series A Convertible Preferred StockForm 10-Q (Exhibit 3.1)August 11, 2016001-37471
Certificate of Designation of Series B Convertible Preferred StockForm 8-K (Exhibit 3.1)February 4, 2019001-37471
Certificate of Designation of Series C Convertible Preferred StockForm 8-K (Exhibit 3.1)November 4, 2019001-37471
Certificate of Designation of Series D Convertible Preferred StockForm 8-K (Exhibit 3.1)April 6, 2020001-37471
Certificate of Designation of Series E Convertible Preferred Stock
Form 8-K (Exhibit 3.1)May 21, 2021001-37471
Amended and Restated Bylaws of the RegistrantForm 8-K (Exhibit 3.2)December 18, 2014333-190728
Amendment to the Amended and Restated Bylaws of the RegistrantForm 8-K (Exhibit 3.1)September 3, 2019001-37471
Form of Common Stock certificateForm 8-K (Exhibit 4.1)December 18, 2014333-190728
Form of Common Stock certificateForm 10-K (Exhibit 4.2)March 23, 2016001-37471
Description of Registered SecuritiesForm 10-K (Exhibit 4.3)March 13, 2020001-37471
2014 Employee, Director and Consultant Equity Incentive Plan#Form 8-K (Exhibit 10.1)December 18, 2014333-190728
Form of Stock Option Award Agreement under the Registrant’s 2014 Employee, Director and Consultant Equity Incentive Plan#Form 8-K (Exhibit 10.2)December 18, 2014333-190728
2016 Employee, Director and Consultant Equity Incentive Plan#Form 8-K (Exhibit 10.1)July 1, 2016001-37471


Form of Stock Option Award Agreement under the Registrant’s 2016 Employee, Director and Consultant Equity Incentive Plan#Form 10-K (Exhibit 10.4)March 30, 2017001-37471
2018 Employee, Director and Consultant Equity Incentive Plan#Form 8-K (Exhibit 10.1)July 26, 2018001-37471
Form of Stock Option Award Agreement under the Registrant’s 2018 Employee, Director and Consultant Equity Incentive Plan#Form S-8 (Exhibit 10.2)August 9, 2018333-226733
Form of Stock Option Award Agreement under the Registrant’s 2020 Employee, Director and Consultant Equity Incentive Plan#Form S-8 (Exhibit 10.2)August 5, 2021333-258502
2018 Employee Stock Purchase Plan#Form 8-K (Exhibit 10.2)July 26, 2018001-37471
2019 Employee, Director and Consultant Equity Incentive Plan#Form 8-K (Exhibit 10.1)July 31, 2019001-37471
2020 Employee, Director and Consultant Equity Incentive Plan#Form 8-K (Exhibit 10.1)June 29, 2020001-37471
2020 Employee, Director and Consultant Equity Incentive Plan, as amended#Form 8-K (Exhibit 10.1)June 29, 2021001-37471
Research and Licensing Agreement by and between Pieris AG and Technische Universität München, dated as of July 26, 2007±Form 10-K (Exhibit 10.10)March 30, 2015333-190728
License and Transfer Agreement by and between the Company and Enumeral Biomedical Holdings, Inc dated as of April 18, 2016±Form 10-Q/A (Exhibit 10.1)July 20, 2016001-37471
Definitive License and Transfer Agreement by and between the Company and Enumeral Biomedical Holdings, Inc. dated as of June 6, 2016±Form 10-Q (Exhibit 10.1)August 11, 2016001-37471
Amendment No.1 to Definitive License and Transfer Agreement by and between the Company and Enumeral Biomedical Holdings, Inc. effective as of January 3, 2017Form 10-K (Exhibit 10.14)March 30, 2017001-37471
Collaboration Agreement by and among the Registrant, Pieris Pharmaceuticals GmbH, Les Laboratoires Servier and Institut de Recherches Internationales Servier, dated as of January 4, 2017±Form 10-K/A (Exhibit 10.15)April 26, 2018001-37471
Non-Exclusive Anticalin Platform Technology License Agreement by and among the Registrant, Pieris Pharmaceuticals GmbH, Les Laboratoires Servier and Institut de Recherches Internationales Servier, dated as of January 4, 2017±Form 10-K/A (Exhibit 10.16)April 26, 2018001-37471
First Amendment to the License and Collaboration Agreement by and between Les Laboratoires Servier, Institut de Recherches Internationales Servier, Pieris Pharmaceuticals, Inc. and Pieris Pharmaceuticals GmbH, effective as of June 16, 2017±Form 10-Q/A (Exhibit 10.4)April 26, 2018001-37471


Letter Amendment to the License and Collaboration Agreement by and between Les Laboratoires Servier, Institut de Recherches Internationales Servier, Pieris Pharmaceuticals, Inc. and Pieris Pharmaceuticals GmbH, effective as of January 3, 2020+Form 10-K (Exhibit 10.16)March 13, 2020001-37471
License & Collaboration Agreement by and between Pieris Pharmaceuticals Inc., Pieris Pharmaceuticals GmbH & Pieris Australia Pty. Limited and AstraZeneca AB, dated as of May 2, 2017±Form 10-Q/A (Exhibit 10.1)April 26, 2018001-37471
Amendment No. 2, dated March 29, 2021, to the License & Collaboration Agreement by and between the Registrant and AstraZeneca AB±Form 10-Q (Exhibit 10.4)May 17, 2021001-37471
Non-Exclusive Anticalin® Platform Technology License Agreement, by and between Pieris Pharmaceuticals Inc., Pieris Pharmaceuticals GmbH and Pieris Australia Pty. Limited and AstraZeneca AB, dated as of May 2, 2017±Form 10-Q/A (Exhibit 10.2)April 26, 2018001-37471
Amendment No. 1, dated March 29, 2021, to the Non-Exclusive Anticalin® Platform Technology License Agreement, dated May 2, 2017, by and between the Registrant and AstraZeneca AB±Form 10-Q (Exhibit 10.5)May 17, 2021001-37471
Subscription Agreement, dated March 29, 2021, by and between the Registrant and AstraZeneca AB±Form 10-Q (Exhibit 10.6)May 17, 2021001-37471
License and Collaboration Agreement by and among the Registrant, Pieris GmbH and Seagen, Inc., dated February 8, 2018±Form 10-Q (Exhibit 10.1)May 10, 2018001-37471
Amendment No. 1 to License and Collaboration Agreement by and among the Registrant, Pieris GmbH and Seagen, Inc., dated June 2, 2020Form 10-Q (Exhibit 10.3)August 10, 2020001-37471
Amended and Restated License and Collaboration Agreement, dated March 24, 2021, by and between the Registrant and Seagen Inc.Form 10-Q (Exhibit 10.1)May 17, 2021001-37471
Combination Study Agreement, dated March 24, 2021, by and between the Registrant and Seagen Inc.Form 10-Q (Exhibit 10.2)May 17, 2021001-37471
Subscription Agreement, dated March 24, 2021, by and between the Registrant and Seagen Inc.Form 10-Q (Exhibit 10.3)May 17, 2021001-37471
Non-Exclusive Anticalin Platform Technology License Agreement by and among the Registrant, Pieris Pharmaceuticals GmbH and Seagen, Inc., dated February 8, 2018±Form 10-Q (Exhibit 10.2)May 10, 2018001-37471
Amendment No. 1 to Non-Exclusive Anticalin Platform Technology License Agreement by and among the Registrant, Pieris Pharmaceuticals GmbH and Seagen, Inc., dated June 2, 2020Form 10-Q (Exhibit 10.3August 10, 2020001-37471


Clinical Trial Collaboration and Supply Agreement by and among the Registrant and Eli Lilly and Company, dated August 10, 2020Form 10-Q (Exhibit 10.1)November 4, 2020001-37471
Exclusive Product License Agreement, dated April 24, 2021, by and among the Registrant, Pieris Pharmaceuticals GmbH and BP Asset XII, Inc.Form 10-Q (Exhibit 10.1)August 5, 2021001-37471
Research Collaboration and License Agreement, dated May 19, 2021, by and among the Registrant, Pieris Pharmaceuticals GmbH and Genentech, Inc.Form 10-Q (Exhibit 10.3)August 5, 2021001-37471
Form of Indemnification Agreement by and between the Registrant and each of its current directors and executive officers#Form 8-K (Exhibit 10.10)December 18, 2014333-190728
Employment Agreement by and between the Registrant and Stephen S. Yoder, dated as of December 17, 2014#Form 8-K (Exhibit 10.15)December 18, 2014333-190728
Employment Agreement by and between the Registrant and Ahmed Mousa, dated as of October 7, 2021#Form 10-Q (Exhibit 10.1)November 2, 2021001-37471
Employment Agreement by and between the Registrant and Tom Bures, dated as of October 7, 2021#Form 10-Q (Exhibit 10.2)November 2, 2021001-37471
Non-Employee Director Compensation Policy, as amended#Form 10-K (Exhibit 10.39)March 2, 2022001-37471
Agreement of Sublease by and between Berenberg Capital Markets LLC and the Registrant, dated as of August 27, 2015Form 10-Q (Exhibit 10.3)November 13, 2015001-37471
Subtenant Recognition and Attornment Agreement, by and among Pieris Pharmaceuticals, Inc., 225 State Street, LLC, and Berenberg Capital Markets LLC, dated as of May 31, 2019Form 10-Q (Exhibit 10.29.1)August 9, 2019001-37471
Lease Agreement by and between Pieris GmbH and Hallbergmoos Grundvermögen GmbH, dated October 24, 2018Form 10-K (Exhibit 10.30)March 18, 2019001-37471
Amendment No. 1 to Lease Agreement by and between Pieris GmbH and Hallbergmoos Grundvermögen GmbH, dated May 21, 2019 (English translation)Form 10-K (Exhibit 10.31)March 13, 2020001-37471
Amendment No. 2 to Lease Agreement by and between Pieris GmbH and Hallbergmoos Grundvermögen GmbH, dated February 13, 2020 (English translation)Form 10-K (Exhibit 10.32)March 13, 2020001-37471
Form of Securities Purchase Agreement, dated December 17, 2014, by and among the Registrant and the PurchasersForm 8-K (Exhibit 10.1)December 23, 2014333-190728
Form of Registration Rights Agreement, dated December 17, 2014, by and among the Registrant and the investors party theretoForm 8-K (Exhibit 10.2)December 23, 2014333-190728
Form of Warrant to Purchase Common Stock, dated December 17, 2014, issued by the RegistrantForm 8-K (Exhibit 10.3)December 23, 2014333-190728


Securities Purchase Agreement, dated June 2, 2016, by and among the Registrant and the Investors named thereinForm 8-K (Exhibit 10.1)June 6, 2016001-37471
Registration Rights Agreement, dated June 2, 2016, by and among the Registrant and the Investors named thereinForm 8-K (Exhibit 10.3)June 6, 2016001-37471
Form of Warrant to purchase Common Stock, dated June 2, 2016, issued by the RegistrantForm 8-K (Exhibit 10.2)June 6, 2016001-37471
Securities Purchase Agreement, dated November 2, 2019, by and among the Company and the Investors named thereinForm 8-K (Exhibit 10.1)November 4, 2019001-37471
Registration Rights Agreement, dated November 2, 2019, by and among the Company and the Investors named thereinForm 8-K (Exhibit 10.3)November 4, 2019001-37471
Form of Warrant to purchase Common Stock, dated November 2, 2019, issued by the RegistrantForm 8-K (Exhibit 10.2)November 4, 2019001-37471
Exchange Agreement, dated January 30, 2019, by and among the Registrant and Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., and Biotechnology Value Trading Fund OS, L.P.Form 8-K (Exhibit 10.1)February 4, 2019001-37471
Exchange Agreement, dated March 31, 2020, by and among the Registrant and Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., and Biotechnology Value Trading Fund OS, L.P.Form 8-K (Exhibit 10.1)April 6, 2020001-37471
Exchange Agreement by and among the Registrant and Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS, L.P., and MSI BVF SPV, L.L.C., dated as of May 20, 2021Form 8-K (Exhibit 10.1)May 21, 2021001-37471
Open Market Sale Agreement, dated as of August 9, 2019, by and between Pieris Pharmaceuticals, Inc. and Jefferies LLCForm 10-Q (Exhibit 10.1)August 9, 2019001-37471
Managing Director Services Agreement by and between Pieris Pharmaceuticals GmbH and Hitto Kaufmann, Ph.D., dated as of August 30, 2019#Form 10-Q (Exhibit 10.2)November 12, 2019001-37471
Non-Qualified Stock Option Agreement by and between the Registrant and Hitto Kaufmann, Ph.D., dated as of August 30, 2019#Form 10-Q (Exhibit 10.3)November 12, 2019001-37471
Form of Non-Qualified Stock Option Agreement by and between the Registrant and Tim Demuth, M.D., Ph.D.Form S-8 (Exhibit 10.3)August 5, 2021333-258502
Corporate Code of Ethics and Conduct and Whistleblower PolicyForm 10-K (Exhibit 14.1)March 31, 2021001-37471
List of SubsidiariesForm 10-K (Exhibit 10.39)44622001-37471
Consent of Ernst & Young LLP*


Certification of Stephen S. Yoder, Chief Executive Officer and President, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
Certification of Thomas Bures, Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
Certification of Stephen S. Yoder, Chief Executive Officer and President, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350**
Certification of Thomas Bures, Chief Financial Officer, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350**
101.INSXBRL Instance Document*
101.SCHXBRL Taxonomy Extension Schema Document*
101.CALXBRL Taxonomy Extension Calculation Linkbase Document
Form 10-K (Exhibit 101.CAL)
March 2, 2022
001-37471
101.DEFXBRL Taxonomy Extension Definition Linkbase DocumentForm 10-K (Exhibit 101.DEF)
March 2, 2022
001-37471
101.LABXBRL Taxonomy Extension Label Linkbase Document*
101.PREXBRL Taxonomy Extension Presentation Linkbase Document*
104Cover Page Interactive Data File (embedded within the Inline XBRL document)*
*Filed herewith
**Furnished herewith
±Confidential treatment received as to portions of the exhibit. Confidential materials omitted and filed separately with the SEC.
+Portions of the exhibit are omitted pursuant to Regulation S-K Item 601(b)(10)(iv). Copies of the unredacted exhibit will be furnished to the SEC upon request.
#Indicates a management contract or compensatory plan





SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
PIERIS PHARMACEUTICALS, INC.
July 6, 2022By: /s/ Stephen S. Yoder
 Stephen S. Yoder
 Chief Executive Officer and President



 EX-23.1 2 pirs12312021ex23110-ka.htm EX-23.1 Document

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

(1)Registration Statements (Form S-3 Nos. 333-212439 and 333-235350),
(2)Registration Statement (Form S-8 No. 333-204487) pertaining to the Pieris Pharmaceuticals, Inc. 2014 Employee, Director and Consultant Equity Incentive Plan,
(3)Registration Statement (Form S-8 No. 333-209308) pertaining to the Pieris Pharmaceuticals, Inc. 2014 Employee, Director and Consultant Equity Incentive Plan and Inducement Stock Option Award for Louis Matis, M.D.,
(4)Registration Statement (Form S-8 No. 333-213771) pertaining to the Pieris Pharmaceuticals, Inc. 2016 Employee, Director and Consultant Equity Incentive Plan,
(5)Registration Statement (Post-Effective Amendment to Form S-1 on Form S-3 No. 333-202123),
(6)Registration Statement (Form S-8 No. 333-221497) pertaining to Inducement Stock Option Awards for Claude Knopf, Allan Reine, M.D, and Ingmar Bruns, M.D., Ph.D,
(7)Registration Statement (Form S-8 No. 333-226733) pertaining to the Pieris Pharmaceuticals, Inc. 2018 Employee, Director and Consultant Equity Incentive Plan,
(8)Registration Statement (Form S-8 No. 333-226735) pertaining to the Pieris Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan,
(9)Registration Statement (Form S-8 No. 333-233194) pertaining to the Pieris Pharmaceuticals, Inc. 2019 Employee, Director and Consultant Equity Incentive Plan,
(10)Registration Statement (Form S-8 No. 333-234625) pertaining to the Non-Qualified Stock Option Agreement, dated August 30, 2019, and
(11)Registration Statement (Form S-8 No. 333-243735) pertaining to the Pieris Pharmaceuticals, Inc. 2020 Employee, Director and Consultant Equity Incentive Plan;
(12)Registration Statements (Form S-3 Nos. 333-256218 and 333-258497)
(13)Registration Statement (Form S-8 No. 333-258502) pertaining to the Pieris Pharmaceuticals, Inc. 2020 Employee, Director and Consultant Equity Incentive Plan, as amended and the Inducement Stock Option Award for Tim Demuth, M.D., Ph.D.

of our report dated March 1, 2022, with respect to the consolidated financial statements of Pieris Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Pieris Pharmaceuticals, Inc. for the year ended December 31, 2021.


/s/ Ernst & Young LLP

Boston, Massachusetts
March 1, 2022

EX-31.1 3 pirs12312021ex31110-ka.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATIONS UNDER SECTION 302
I, Stephen S. Yoder, certify that:
1. I have reviewed the Amendment No. 1 to the Annual Report on Form 10-K/A of Pieris Pharmaceuticals, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Dated: July 6, 2022
/s/ Stephen S. Yoder
Stephen S. Yoder
Title:Chief Executive Officer and President (principal executive officer)

 EX-31.2 4 pirs12312021ex31210-ka.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATIONS UNDER SECTION 302
I, Thomas Bures, certify that:
1. I have reviewed the Amendment No. 1 to the Annual Report on Form 10-K/A of Pieris Pharmaceuticals, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Dated: July 6, 2022
/s/ Thomas Bures
Thomas Bures
Title:Senior VP, Chief Financial Officer and Treasurer (principal financial officer)


 EX-32.1 5 pirs12312021ex32110-ka.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATIONS UNDER SECTION 906
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of Pieris Pharmaceuticals, Inc., a Nevada corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:
The Amendment No. 1 to the Annual Report on Form 10-K/A for the year ended December 31, 2021 (the “Amendment”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Amendment fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Dated: July 6, 2022/s/ Stephen S. Yoder
Stephen S. Yoder
Title:Chief Executive Officer and President
(principal executive officer)


 EX-32.2 6 pirs12312021ex32210-ka.htm EX-32.2 Document

Exhibit 32.2
CERTIFICATIONS UNDER SECTION 906
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of Pieris Pharmaceuticals, Inc., a Nevada corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:
The Amendment No. 1 to the Annual Report on Form 10-K/A for the year ended December 31, 2021 (the “Amendment”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Amendment fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Dated: July 6, 2022/s/ Thomas Bures
Thomas Bures
Title:Senior VP, Chief Financial Officer and Treasurer
(principal financial officer)

 EX-101.SCH 7 pirs-20211231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0002002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 8 pirs-20211231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Address, Postal Zip Code Entity Address, Postal Zip Code Auditor Location Auditor Location Entity Interactive Data Current Entity Interactive Data Current Document Transition Report Document Transition Report Document Period End Date Document Period End Date Entity Central Index Key Entity Central Index Key Audit Information [Abstract] Audit Information [Abstract] Entity Public Float Entity Public Float Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Entity Voluntary Filers Entity Voluntary Filers Document Annual Report Document Annual Report Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Entity Filer Category Entity Filer Category Auditor Firm ID Auditor Firm ID Entity Emerging Growth Company Entity Emerging Growth Company Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Entity Current Reporting Status Entity Current Reporting Status Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Address, Address Line Two Entity Address, Address Line Two Entity Registrant Name Entity Registrant Name ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Entity Small Business Entity Small Business Local Phone Number Local Phone Number Entity Address, State or Province Entity Address, State or Province City Area Code City Area Code Entity Shell Company Entity Shell Company Document Type Document Type Entity Address, Country Entity Address, Country Document Fiscal Year Focus Document Fiscal Year Focus Auditor Name Auditor Name Cover [Abstract] Entity Address, City or Town Entity Address, City or Town Entity File Number Entity File Number Amendment Flag Amendment Flag Trading Symbol Trading Symbol Entity Tax Identification Number Entity Tax Identification Number Document Fiscal Period Focus Document Fiscal Period Focus Current Fiscal Year End Date Current Fiscal Year End Date EX-101.PRE 9 pirs-20211231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover - USD ($)
 12 Months Ended
Dec. 31, 2021
Feb. 24, 2022
Jun. 30, 2021
Cover [Abstract]      
Document Type 10-K/A    
Document Annual Report true    
Document Period End Date Dec. 31, 2021    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 001-37471    
Entity Registrant Name PIERIS PHARMACEUTICALS, INC.    
Entity Incorporation, State or Country Code NV    
Entity Tax Identification Number 30-0784346    
Entity Address, Address Line One 255 State Street    
Entity Address, Address Line Two 9th Floor    
Entity Address, City or Town Boston    
Entity Address, State or Province MA    
Entity Address, Country US    
Entity Address, Postal Zip Code 2109    
City Area Code 857    
Local Phone Number 246-8998    
Title of 12(b) Security Common Stock, par value $0.001 per share    
Trading Symbol PIRS    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag false    
Entity Shell Company false    
Entity Public Float     $ 170,606,113
Entity Common Stock, Shares Outstanding   74,077,417  
Documents Incorporated by Reference Certain information required in Part III of this Annual Report on Form 10-K is incorporated from the Registrant’s Proxy Statement for the 2022 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission.    
Amendment Flag false    
Document Fiscal Year Focus 2021    
Document Fiscal Period Focus FY    
Entity Central Index Key 0001583648    
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.22.2
Audit Information
 12 Months Ended
Dec. 31, 2021
Audit Information [Abstract]  
Auditor Name Ernst & Young LLP
Auditor Location Boston, Massachusetts
Auditor Firm ID 42
XML 12 pirs-20211231_htm.xml IDEA: XBRL DOCUMENT 0001583648 2021-01-01 2021-12-31 0001583648 2021-06-30 0001583648 2022-02-24 iso4217:USD shares false 2021 FY 0001583648 10-K/A true 2021-12-31 --12-31 false 001-37471 PIERIS PHARMACEUTICALS, INC. NV 30-0784346 255 State Street 9th Floor Boston MA US 2109 857 246-8998 Common Stock, par value $0.001 per share PIRS NASDAQ No No Yes Yes Non-accelerated Filer true false false false 170606113 74077417 Certain information required in Part III of this Annual Report on Form 10-K is incorporated from the Registrant’s Proxy Statement for the 2022 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission. Ernst & Young LLP Boston, Massachusetts 42 EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 3 39 1 false 0 0 false 2 false false R1.htm 0001001 - Document - Cover Sheet http://www.pieris.com/role/Cover Cover Cover 1 false false R2.htm 0002002 - Document - Audit Information Sheet http://www.pieris.com/role/AuditInformation Audit Information Cover 2 false false All Reports Book All Reports pirs-20211231.htm pirs-20211231.xsd pirs-20211231_lab.xml pirs-20211231_pre.xml pirs12312021ex23110-ka.htm pirs12312021ex31110-ka.htm pirs12312021ex31210-ka.htm pirs12312021ex32110-ka.htm pirs12312021ex32210-ka.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "pirs-20211231.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 3, "dts": { "inline": { "local": [ "pirs-20211231.htm" ] }, "labelLink": { "local": [ "pirs-20211231_lab.xml" ] }, "presentationLink": { "local": [ "pirs-20211231_pre.xml" ] }, "schema": { "local": [ "pirs-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 41, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 39, "memberCustom": 0, "memberStandard": 0, "nsprefix": "pirs", "nsuri": "http://www.pieris.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pirs-20211231.htm", "contextRef": "i7163082621b64229a86646e30dde0341_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.pieris.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pirs-20211231.htm", "contextRef": "i7163082621b64229a86646e30dde0341_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pirs-20211231.htm", "contextRef": "i7163082621b64229a86646e30dde0341_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "false", "longName": "0002002 - Document - Audit Information", "role": "http://www.pieris.com/role/AuditInformation", "shortName": "Audit Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "pirs-20211231.htm", "contextRef": "i7163082621b64229a86646e30dde0341_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r4", "r5", "r6" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/AuditInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r4", "r5", "r6" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r4", "r5", "r6" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r4", "r5", "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r4", "r5", "r6" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.pieris.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "pirs_AuditInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Audit Information [Abstract]", "label": "Audit Information [Abstract]" } } }, "localname": "AuditInformationAbstract", "nsuri": "http://www.pieris.com/20211231", "xbrltype": "stringItemType" } }, "unitCount": 2 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r4": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r5": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r6": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r7": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r8": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r9": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" } }, "version": "2.1" } ZIP 19 0001583648-22-000057-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001583648-22-000057-xbrl.zip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